Press Release : ObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021

 
   - Data from PROLONG Phase 2a proof-of-concept study of ebopiprant 
(OBE022) for spontaneous preterm labor to be discussed in an oral 
presentation - 
 
   GENEVA, Switzerland and BOSTON, MA -- June 2, 2021 -- ObsEva SA (NASDAQ: 
OBSV) (SIX: OBSN), a biopharmaceutical company developing and 
commercializing novel therapies to improve women's reproductive health, 
today announced the presentation of clinical data from the PROLONG Phase 
2a proof-of-concept study of ebopiprant for spontaneous preterm labor at 
the Royal College of Obstetricians and Gynaecologists (RCOG) Virtual 
World Congress 2021, being held June 9-12. Ebopiprant is ObsEva's first 
in class, orally active selective prostaglandin F(2) (ALPHA>) (PGF(2) 
(ALPHA>) ) receptor antagonist designed to treat preterm labor. 
 
   Details of the oral presentation are as follows: 
 
   Title: A Randomised, Placebo-Controlled, Proof-of-Concept Trial of 
Ebopiprant for Spontaneous Preterm Labor (PROLONG) 
 
   Abstract ID: 601 
 
   Presenter: Ben Mol, Ph.D., M.D., Professor of Obstetrics and Gynaecology, 
Monash Medical Centre, Melbourne Australia 
 
   Session Date: Saturday, June 12, 2021 
 
   Session Time: 8:10-8:20 a.m. Greenwich Mean Time 
 
   The link to the session will be available under "Events Calendar" in the 
investors section of ObsEva's website at www.ObsEva.com 
 
 
 
   About ObsEva 
 
   ObsEva is a biopharmaceutical company developing and commercializing 
novel therapies to improve women's reproductive health and pregnancy. 
Through strategic in-licensing and disciplined drug development, ObsEva 
has established a late-stage clinical pipeline with development programs 
focused on treating endometriosis, uterine fibroids and preterm labor. 
ObsEva is listed on the Nasdaq Global Select Market and is trading under 
the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is 
trading under the ticker symbol "OBSN". For more information, please 
visit www.ObsEva.com. 
 
   About RCOG 
 
   The RCOG is a medical charity that champions the provision of 
high-quality women's healthcare in the UK and beyond. It is dedicated to 
encouraging the study and advancing the science and practice of 
obstetrics and gynaecology. It does this through postgraduate medical 
education and training and the publication of clinical guidelines and 
reports on aspects of the specialty and service provision. If you would 
like to request a Press pass to the congress please email 
[e-mail] 
https://www.globenewswire.com/Tracker?data=U9TcW7Ml4ARW_Eg_HORmceGRjk-7XC-mCnkoL29b-VKLwLvF3gm5azFZaV2owBXgDmRNf4fq851cfB37rDZwezaTPEJM7qfvwIXHq-J3dp4= 
. 
 
   Cautionary Note Regarding Forward Looking Statements 
 
   Any statements contained in this press release that do not describe 
historical facts may constitute forward-looking statements as that term 
is defined in the Private Securities Litigation Reform Act of 1995. 
These statements may be identified by words such as "believe", "expect", 
"may", "plan", "potential", "will", and similar expressions, and are 
based on ObsEva's current beliefs and expectations. These 
forward-looking statements include expectations regarding the clinical 
development of and commercialization plans for ObsEva's product 
candidates, expectations regarding regulatory and development milestones, 
including the potential timing of regulatory submissions to the EMA and 
FDA and ObsEva's ability to obtain and maintain regulatory approvals for 
its product candidates, and the results of interactions with regulatory 
authorities. These statements involve risks and uncertainties that could 
cause actual results to differ materially from those reflected in such 
statements. Risks and uncertainties that may cause actual results to 
differ materially include uncertainties inherent in the conduct of 
clinical trials and clinical development, including the risk that the 
results of earlier clinical trials may not be predictive of the results 
of later stage clinical trials, related interactions with regulators, 
ObsEva's reliance on third parties over which it may not always have 
full control, the impact of the novel coronavirus outbreak, and other 
risks and uncertainties that are described in the Risk Factors section 
of ObsEva's Annual Report on Form 20-F for the year ended December 31, 
2020 filed with Securities and Exchange Commission (SEC) on March 5, 
2021 and other filings ObsEva makes with the SEC. These documents are 
available on the Investors page of ObsEva's website at 
http://www.ObsEva.com. Any forward-looking statements speak only as of 
the date of this press release and are based on information available to 
ObsEva as of the date of this release, and ObsEva assumes no obligation 
to, and does not intend to, update any forward-looking statements, 
whether as a result of new information, future events or otherwise. 
 
 
 
   For further information, please contact: 
 
   CEO Office contact 
 
   Shauna Dillon 
 
   [e-mail] 
https://www.globenewswire.com/Tracker?data=csE0_q7RqyvuppYY7U0ExtH9eyRx8OjrY6tYmAzwbsCCzTEkU81Fui07a42HwLSxtRwFVLrhaqd2ebttoC3CupBB30730QHH91q9DZNI4bI= 
 
 
   [phone] 
 
   Investor Contact: 
 
   Joyce Allaire 
 
   [e-mail] 
https://www.globenewswire.com/Tracker?data=N5PBzv1-g0WJChKNDrH2Tn0JBErCH1a1K7ppvFgYHvXlmQWgaLiyA3zdADfLhQUk4vQkOdZWRl-oxzHuBcyLqCL8EXaig0vUigV58ALKKJEzd3ojhz6HNHk9L-PBgwYO 
 
 
   [phone] 
 
 
 
   # 
 
 
 
   Attachment 
 
 
   -- Press Release in Pdf 
      https://ml-eu.globenewswire.com/Resource/Download/3ba1c1ec-ef98-4f09-b0d3-9710e2485e99

(END) Dow Jones Newswires

June 02, 2021 01:00 ET (05:00 GMT)